Loading
Obesity / Overweight / Petrelintide · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for a completed trial of petrelintide (a novel GLP-1 receptor agonist) versus placebo in overweight or obese adults with type 2 diabetes, with body weight change as the primary outcome. No efficacy or safety results are posted in this registry record, so the evidence base remains unreported and cannot yet be evaluated.
Phase 2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Overweight, Type 2 Diabetes, Obesity; age from 18 Years. Intervention: Treatment A: Petrelintide Dose 1; Treatment C: Petrelintide Dose 2; Treatment E: Petrelintide Dose 3. Compared with: Treatment B: Petrelintide Placebo Dose 1 — Placebo Comparator; Treatment D: Petrelintide Placebo Dose 2 — Placebo Comparator; Treatment F: Petrelintide Placebo Dose 3 — Placebo Comparator. n = 221. 48 sites: United States.
This is a Phase 2 registry record for a completed trial of petrelintide (a novel GLP-1 receptor agonist) versus placebo in overweight or obese adults with type 2 diabetes, with body weight change as the primary outcome. No efficacy or safety results are posted in this registry record, so the evidence base remains unreported and cannot yet be evaluated.
Results not yet reported in this registry record; efficacy, safety, and tolerability data are absent.
Clinicians should note that this Phase 2 trial has completed enrollment and recruitment but results are not yet available in this registry record. Once results are posted, this trial will provide preliminary efficacy and safety data on petrelintide dosing in this population, but confirmatory Phase 3 evidence will be needed before clinical adoption.
Phase 2 trial with completed enrollment but no results posted; design and primary outcome are specified but efficacy and safety data are not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that this Phase 2 trial has completed enrollment and recruitment but results are not yet available in this registry record. Once results are posted, this trial will provide preliminary efficacy and safety data on petrelintide dosing in this population, but confirmatory Phase 3 evidence will be needed before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06926842). This is a study registration, not published results. Lead sponsor: Zealand Pharma. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 221 participants (ACTUAL). Conditions: Overweight, Type 2 Diabetes, Obesity. Interventions: DRUG: Petrelintide; OTHER: Placebo. Primary outcome measures: Percentage Change in Body Weight , From Baseline (Day 1) to Weeks 28. Brief summary: The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.